Loading clinical trials...

Development of Green Mei Products for the Prevention of Metabolic Syndrome | Clinical Trials | Clareo Health

COMPLETEDNA

Development of Green Mei Products for the Prevention of Metabolic Syndrome

NCT05039437•Chung Shan Medical University

Summary

The aim of this study is to investigate the antihypertensive effects of Mei-Gin formula-4 (MGF-4) and Mei-Gin formula-7.

Detailed Description

It's a randomized, and single-blind trial and was designed to evaluate the effects of MGFs (MGF-4 and MGF-4) on blood pressure. 50 participants with hypertension (systolic blood pressure between 130-179 mmHg or diastolic blood pressure between 85-109 mmHg) who did not accept any hypertension medication were randomized allocated to either MGF-4 or MGF-7 group. Participants were instructed to take 4 capsules of MGF-4 or MGF-7 daily throughout the duration of the 8 weeks intervention study. After treatment, the change of the blood pressure and relative mechanism were analyzed.

Eligibility

Age

20 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•The age of the subject is 20 to 70 years old.
•The subject is a patient with hypertension (SBP is between 130-179 mmHg, DBP is between 85-109mmHg, one of the two can be diagnosed), and there are no serious illnesses requiring hospitalization during the study period treatment.
•No hypertension medication.
•The subject can understand the test process described in the consent form and the possible potential risks and benefits, and able to sign the consent form.
•The subjects shall observe diet control during the trial period.

Exclusion Criteria

•Subjects diagnosed with cancer and still under active treatment.
•Subjects diagnosed with heart disease and still under active treatment.
•Other drugs are used, whose pharmacological effects may affect blood pressure or may aggravate the effects of drugs.
•Subjects who have systemic infection and need systemic antibiotics.

Locations (1)

Chung Shan Medical University

Taichung, South, Taiwan

Key Dates

Start Date

June 15, 2019

Primary Completion Date

December 1, 2019

Completion Date

December 31, 2019

Last Updated

September 9, 2021

Enrollment

ACTUAL participants

Conditions

Hypertension

Interventions

MGF-4

DIETARY_SUPPLEMENT

MGF-7

DIETARY_SUPPLEMENT

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITING

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

NCT07480265

Hypertension (HTN)Hyperhomocysteinemia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 9, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Development of Green Mei Products for the Prevention of Metabolic Syndrome

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets